493. From Data Science to Drug Design: How AI Shifts Discovery, Target Validation, and Portfolio Construction (Jim Tananbaum)
View Transcript
Episode Description
Jim Tananbaum of Foresite Capital joins Nick to discuss From Data Science to Drug Design: How AI Shifts Discovery, Target Validation, and Portfolio Construction. In this episode we cover:
- Data Science and Investment Approach
- Investment Practices and Market Conditions
- China's Role in Biotech and Regulatory Considerations
- Impact of AI on Biotech and Healthcare
- Healthcare Adoption of AI and Preventive Measures
- Payers and Insurance Companies' Role
- Lessons from Successful Investments
- Generating Liquidity in a Sluggish Market
- Future of GLP-1 Agonists
Guest Links:
The host of The Full Ratchet is Nick Moran of New Stack Ventures, a venture capital firm committed to investing in founders outside of the Bay Area.
We’re proud to partner with Ramp, the modern finance automation platform. Book a demo and get $150—no strings attached.
Want to keep up to date with The Full Ratchet? Follow us on social. You can learn more about New Stack Ventures by visiting our LinkedIn and Twitter.